Changes in Beneficial Ownership · 4
Vericel Corporation
VCELNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4.xml
Filing details
- Report period
- 2026-08-12
- Issuer
- Vericel Corp
- Issuer CIK
- 0000887359
- Trading symbol
- VCEL
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- MCLAUGHLIN KEVIN F
- Reporting owner CIK
- 0001214938
- Relationship
- Director
- Address
- C/O VERICEL CORPORATION, 25 BLUE SKY DRIVE, BURLINGTON, MA, 01803
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-12 | M · Form 4 | 7,000 | A | 13.05 | 25,300 | D |
| Common Stock | 2026-08-12 | S · Form 4 | 7,000 | D[F1] | 44.53 | 18,300 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 13.05 | 2026-08-12 | M · Form 4 | 7,000 | A | 0 | [F2] | 2028-05-02 | Common Stock | 7,000 | 7,000 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025.↩ 1
- F2
- These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.↩ 1
Signature 1
- Signed
- /s/ Sean Flynn, as Attorney-in-Fact for Kevin McLaughlin
- Date
- 2026-08-14
Company context
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. For more information, please visit www.vcel.com.